Masebe, TracyBessong, Obong PascalNdip, Roland NdipMeyer, Debra2016-10-302016-10-302014-06-26Masebe, T., Bessong, O.P., Ndip, R.N. & Meyer, D. 2014. Genetic Variants of APOC3 Promoter and HLA-B genes in an HIV Infected Cohort in Northern South Africa: A Pilot Study. http://hdl.handle.net/11602/6581422-0067doi: 10.3390/ijms150711403http://hdl.handle.net/11602/658Publication of this article was funded by the Universiry of Venda: HIV/AIDS & Global Health Research Programme, Department of MicrobiologyCITATION: Masebe Tracy et al. (2014): Genetic variants of APOC3 Promoter and HLA-B Genes in an HIV Infected Cohort in Northern South Africa: A Pilot Study, International Journal of Molecular Sciences, 15,11403-11415; doi.: 10.3390/ijms157111403.Metabolic disorders and hypersensitivities affect tolerability and impact adherence to highly active antiretroviral therapy (HAART). The aim of this study was to determine the prevalence of C-482T/T-455C variants in the Apolipoprotein C3 (APOC3) promoter gene and Human leukocyte antigen (HLA)-B*57:01, known to impact lipid metabolic disorders and hypersensitivity respectively; and to correlate genotypes with gender, CD4+ cell count and viral load in an HIV infected cohort in northern South Africa. Frequencies of C-482 and T-455 polymorphisms in APOC3 were determined by restriction fragment length polymorphism analysis. Allele determination for HLA-B was performed with Assign SBT software in an HLA library. Analysis of APOC3 C-482 site revealed a prevalence of 196/199 (98.5%) for CC, 1/199 (0.5%) for CT and 2/199 (1.0%) for TT genotype (p = 0.000 with 1° of freedom; χ2 = 126.551). For the T-455 site, prevalences were: 69/199 (35%) for TT and 130/199 (65%) for the CC genotype (p = 0.000 with 1° of freedom; χ2 = 199). There was no association between gender and the presence of −482 (p = 1; χ2 = 0.00001) or −455 genotypes (p = 0.1628; χ2 = 1.9842). There was no significant difference in the increase in CD4+ cell count irrespective of genotypes. Significant increases in CD4+ cell count were observed in males and females considering the −455C OPEN ACCESS Int. J. Mol. Sci. 2014, 15 11404 genotype, but not in males for the −455T genotype. Viral load decreases were significant with the −455C and −482C genotypes irrespective of gender. HLA-B*57:01 was not identified in the study cohort. The apparently high prevalence of APOC3 T-455CC genotype needs confirmation with a larger samples size and triglyceride measurements to support screening of patients to pre-empt HAART associated lipid disorders.enGenetic variantsUCTDAPOC3HLA-BHighly active antiretroviral therapyLipid disordersSouth AfricaGenetic Variants of APOC3 Promoter and HLA-B genes in an HIV Infected Cohort in Northern South Africa: A Pilot StudyArticleMasebe T, Bessong OP, Ndip RN, Meyer D. Genetic Variants of APOC3 Promoter and HLA-B genes in an HIV Infected Cohort in Northern South Africa: A Pilot Study. 2014; http://hdl.handle.net/11602/658.Masebe, T., Bessong, O. P., Ndip, R. N., & Meyer, D. (2014). Genetic Variants of APOC3 Promoter and HLA-B genes in an HIV Infected Cohort in Northern South Africa: A Pilot Study. http://hdl.handle.net/11602/658Masebe, Tracy, Obong Pascal Bessong, Roland Ndip Ndip, and Debra Meyer "Genetic Variants of APOC3 Promoter and HLA-B genes in an HIV Infected Cohort in Northern South Africa: A Pilot Study." (2014) http://hdl.handle.net/11602/658TY - AU - Masebe, Tracy AU - Bessong, Obong Pascal AU - Ndip, Roland Ndip AU - Meyer, Debra AB - Metabolic disorders and hypersensitivities affect tolerability and impact adherence to highly active antiretroviral therapy (HAART). The aim of this study was to determine the prevalence of C-482T/T-455C variants in the Apolipoprotein C3 (APOC3) promoter gene and Human leukocyte antigen (HLA)-B*57:01, known to impact lipid metabolic disorders and hypersensitivity respectively; and to correlate genotypes with gender, CD4+ cell count and viral load in an HIV infected cohort in northern South Africa. Frequencies of C-482 and T-455 polymorphisms in APOC3 were determined by restriction fragment length polymorphism analysis. Allele determination for HLA-B was performed with Assign SBT software in an HLA library. Analysis of APOC3 C-482 site revealed a prevalence of 196/199 (98.5%) for CC, 1/199 (0.5%) for CT and 2/199 (1.0%) for TT genotype (p = 0.000 with 1° of freedom; χ2 = 126.551). For the T-455 site, prevalences were: 69/199 (35%) for TT and 130/199 (65%) for the CC genotype (p = 0.000 with 1° of freedom; χ2 = 199). There was no association between gender and the presence of −482 (p = 1; χ2 = 0.00001) or −455 genotypes (p = 0.1628; χ2 = 1.9842). There was no significant difference in the increase in CD4+ cell count irrespective of genotypes. Significant increases in CD4+ cell count were observed in males and females considering the −455C OPEN ACCESS Int. J. Mol. Sci. 2014, 15 11404 genotype, but not in males for the −455T genotype. Viral load decreases were significant with the −455C and −482C genotypes irrespective of gender. HLA-B*57:01 was not identified in the study cohort. The apparently high prevalence of APOC3 T-455CC genotype needs confirmation with a larger samples size and triglyceride measurements to support screening of patients to pre-empt HAART associated lipid disorders. DA - 2014-06-26 DB - ResearchSpace DP - Univen KW - Genetic variants KW - APOC3 KW - HLA-B KW - Highly active antiretroviral therapy KW - Lipid disorders KW - South Africa LK - https://univendspace.univen.ac.za PY - 2014 SM - 1422-0067 T1 - Genetic Variants of APOC3 Promoter and HLA-B genes in an HIV Infected Cohort in Northern South Africa: A Pilot Study TI - Genetic Variants of APOC3 Promoter and HLA-B genes in an HIV Infected Cohort in Northern South Africa: A Pilot Study UR - http://hdl.handle.net/11602/658 ER -